Intestinal Pseudo-Obstruction Treatment Market Analysis 2024 -2033: Forecasted Market Size, Top Segments, And Largest Region | F. Hoffmann-La Roche AG, Merck Sharp & Dohme Corp, Bayer AG, Sanofi S.A

The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033

The Business Research Company offers in-depth market insights through Intestinal Pseudo-Obstruction Treatment Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.

Market Size And Growth Forecast:
The intestinal pseudo-obstruction treatment market size has grown strongly in recent years. It will grow from $22.06 billion in 2023 to $23.46 billion in 2024 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to increased recognition and diagnosis, advancements in medical imaging, advancements in gastrointestinal motility testing, global healthcare access.

The intestinal pseudo-obstruction treatment market size is expected to see strong growth in the next few years. It will grow to $29.04 billion in 2028 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to research and drug development, telemedicine and remote monitoring, patient education and support, reimbursement policies. Major trends in the forecast period include advanced gastrointestinal motility testing, immunomodulatory therapies, nutritional interventions, data analytics and ai.

Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=12995&type=smp

Market Segmentation:
The main classes of drugs included in intestinal pseudo-obstruction treatment are antibiotics, antidepressants and antidiarrheals. Antibiotics are a class of powerful medications used to treat bacterial infections in humans and animals. The various types of treatments are included, such as medication, surgery, diet, decompression and others, which are administered through several routes, including oral, intravenous and others. The various diagnoses, including physical examination, biopsy, blood test, gastric emptying tests, imaging tests and others, which are used by several end users, including clinics, hospitals and others.

Major Driver - Parkinson's Disease-Associated Gastrointestinal Issues Boost Intestinal Pseudo-Obstruction Treatment Market
The rising cases of Parkinson's disease are expected to propel the growth of the intestinal pseudo-obstruction treatment market going forward. Parkinson's disease refers to a neurodegenerative condition that primarily affects the dopamine-producing neurons in the substantia nigra, a particular region of the brain. There is an increased incidence of IPO in individuals with Parkinson's disease because it affects the enteric nervous system, causing gastrointestinal dysmotility that can result in megacolon or intestinal blockage, including acute colonic pseudo-obstruction. For instance, in December 2022, according to the Parkinson's Foundation, a US-based non-profit group, Parkinson's disease (PD) was identified in roughly 90,000 Americans annually, compared to the previous estimate of 60,000 diagnoses annually, there has been a sharp 50% increase. In addition, it is predicted that by 2030, there will be 1.2 million people worldwide with Parkinson's disease. Therefore, the rising cases of Parkinson's disease drive the growth of the intestinal pseudo-obstruction treatment market.

Competitive Landscape:
Major players in the intestinal pseudo-obstruction treatment market are F. Hoffmann-La Roche AG, Merck Sharp & Dohme Corp, Bayer AG, Sanofi S.A., AstraZeneca PLC, GSK PLC, Takeda Pharmaceutical Company Limited, Amgen PLC, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Mylan N.V., Biogen Inc., Penn Medicine, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Cipla Inc., Dr. Reddy's Laboratories Ltd., Allergan PLC, Torrent Pharmaceuticals Limited, Basilea Pharmaceutica Ltd., Paratek Pharmaceuticals Inc., Melinta Therapeutics LLC, Tetraphase Pharmaceuticals Inc., Callisto Pharmaceuticals Inc.

Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/intestinal-pseudo-obstruction-treatment-global-market-report

Top Trend - Pharmaceutical Innovations Embrace Plant-Based Solutions For Intestinal Pseudo-Obstruction Treatment
Major companies operating in the intestinal pseudo-obstruction treatment market are integrating their efforts into adopting new solutions towards plant-based solution to sustain their position in the market. Plant-based supplements can help reduce the risk of bowel obstruction by promoting regular bowel movements and reducing inflammation. For instance, in August 2021, Enzymedica Inc., a US-based pharmaceutical company, launched Gut Motility, a new plant-based supplement to promote healthier gastrointestinal motility and gastric emptying. It is a first-of-its-kind nutraceutical formulation designed to address problems with digestive transit and stomach emptying that combines artichoke leaf extract, ginger root CO2 extract and apple cider vinegar. The main component of Gut Motility is ProDigest, a triple-standardized artichoke leaf extract and ginger root CO2 extract blend shown in clinical studies to assist good digestive transit. The mixture also has the unique addition of apple cider vinegar, made from apples grown in the United States, to support a balanced pH in the digestive tract and optimize metabolism.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Intestinal Pseudo-Obstruction Treatment Market Characteristics
3. Intestinal Pseudo-Obstruction Treatment Market Trends And Strategies
4. Intestinal Pseudo-Obstruction Treatment Market - Macro Economic Scenario
5. Intestinal Pseudo-Obstruction Treatment Market Size And Growth
…..
27. Intestinal Pseudo-Obstruction Treatment Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.

This release was published on openPR.